Advanced Solid Tumor
Conditions
Brief summary
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.
Detailed description
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.The frequency of administration and the dose to be administered in subsequent clinical studies will be determined based on a combination of preliminary data.
Interventions
DRUGQLS12004
Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF); 2. Age ≥ 18 years when ICF is signed; 3. At least one target lesion as defined per RECIST Version (v) 1.1; 4. Dose escalation phase: Pts with histologically or cytologically confirmed advanced solid tumors, who have failed standard therapy or for whom no standard therapy is available; 5. Dose escalation phase: HR+/HER2-advanced breast cancer that has failed prior CDK4/6 inhibitor combined with endocrine therapy; 6. Eastern Cooperative Oncology Group performance status of 0 or 1; 7. Adequate hematologic and organ function; 8. Female subjects who are not pregnant or breastfeeding 9. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 90 days after last dose.
Exclusion criteria
1. Subjects with major cardiovascular and cerebrovascular diseases; 2. Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug; 3. Subjects who have received chemotherapy, endocrine therapy, immunotherapy, and targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product; 4. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study; 5. HIV-positive or syphilis spiral antibody-positive persons; 6. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose, or the need for elective surgery during the trial; 7. Known hypersensitivity to the test drug or any of its excipients; 8. History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AEs, TEAEs, TRAEs, SAEs | up to 2 years | Incidence, severity and relevance to the trial drug of adverse events (AEs), treatment-related adverse events (TEAEs), treatment-related adverse events (TRAEs) and serious adverse events (SAEs) |
| DLT | Up to 21 days after the first dose | Dose-limiting toxicity |
| MTD | Up to 21 days after the first dose | maximum tolerated dose |
| RP2D | Up to 21 days after the first dose | recommended phase II dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | up to 2 years | Progression-free Survival |
| Tmax | up to 2 years | Time to Reach Maximum (peak) Plasma Concentration Following Drug Administration |
| OS | up to 2 years | Objective Response Rate |
| Cmax | up to 2 years | Maximum Plasma Drug Concentration |
| ORR | up to 2 years | Objective Response Rate |
| DCR | up to 2 years | Disease Control Rate |
Countries
China
Contacts
Primary ContactZefei Jiang, Professor
Outcome results
None listed